BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 14, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 28, 2009
View Archived Issues
Antihypertensive agent candesartan shows clinical promise for prevention of cognitive decline
Read More
Mimopezil SR implants are well-tolerated with comparable efficacy to donepezil in AD
Read More
Vertex claims ABC and CFTR modulators for the treatment of cystic fibrosis
Read More
Bayer Schering Pharma developing Toll-like receptor modulators as anti-inflammatory agents
Read More
Bayer Schering Pharma describes new progesterone receptor antagonists for gynecological disorders
Read More
NeuroSearch prepares and tests novel nicotinic alpha7 receptor agonists
Read More
Merz launches Xeomin in Canada for several neuromuscular conditions
Read More
QRxPharma initiates phase II proof-of-concept study for MoxDuo in pain
Read More
MJFF awards grant to Targacept to fund research into levodopa-induced dyskinesias
Read More
Hisamitsu initiates cash tender offer for all outstanding shares of Noven common stock
Read More
CHMP issues positive opinion for Regeneron's rilonacept for CAPS
Read More
PolyMedix and UMass receive military funding to develop defensin mimetics
Read More
FDA approves Aradigm's IND for phase IIb study of inhaled liposomal ciprofloxacin in BE
Read More
Merck Serono considers appealing CHMP negative opinion on Erbitux for NSCLC
Read More
CHMP issues positive opinion on Keppra in children with partial-onset epilepsy
Read More
Genmab completes recruitment in phase II Arzerra study in relapsed DLBCL
Read More
Tamibarotene receives positive opinion for orphan medicinal product status
Read More
Orexo reports phase III results for KW-2246 in Japan
Read More
NeurogesX reports preliminary results of FDA-requested Qutenza study
Read More
Ambrilia terminates phase III clinical study of octreotide in patients with acromegaly
Read More
Alizyme suspends trading in ordinary shares and will be placed in administration
Read More
Seattle Genetics commences phase II brentuximab vedotin retreatment trial
Read More
Raltegravir shows comparable antiretroviral activity to efavirenz in HIV-1; phase II data disclosed
Read More
The HNE inhibitor POL-6014 shows potential in mouse model of acute lung injury
Read More
Anti-inflammatory agent bindarit reduces MCP-1 excretion in patients with active lupus nephritis
Read More
